ReShape LifesciencesRSLS
RSLS
About: Reshape Lifesciences Inc is a medical device company focused on technologies to treat obesity and metabolic diseases. The company's current portfolio includes the LAP-BAND, an Adjustable Gastric Banding System, ReShapeCare virtual health coaching program, ReShape Market Place, including ReShape Optimize a supplemental multivitamin, the Obalon Balloon System, the first and only swallowable gas-filled balloon system, and the Diabetes Bloc-Stim Neuromodulation, a technology under development as a new treatment for type 2 diabetes mellitus. Geographically, the company operates in the United States, Australia, Europe, and the Rest of world, and the majority of its revenue is generated from the United States.
Employees: 18
0
Funds holding %
of 7,425 funds
–
Analysts bullish %
Fund manager confidence
Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)
1,090% more capital invested
Capital invested by funds: $7.16K [Q3] → $85.2K (+$78.1K) [Q4]
2.44% more ownership
Funds ownership: 0.25% [Q3] → 2.69% (+2.44%) [Q4]
10% less funds holding
Funds holding: 10 [Q3] → 9 (-1) [Q4]
50% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 2
Research analyst outlook
We haven’t received any recent analyst ratings for RSLS.
Financial journalist opinion
Based on 5 articles about RSLS published over the past 30 days
Neutral
GlobeNewsWire
2 days ago
ReShape Lifesciences® Receives Notice of Allowance for Key U.S. Patent Related to an Intragastric Balloon System
Patent Expands and Strengthens Intellectual Property Portfolio Around a Swallowable and Degradable Intragastric Device Patent Expands and Strengthens Intellectual Property Portfolio Around a Swallowable and Degradable Intragastric Device
Neutral
GlobeNewsWire
1 week ago
ReShape Lifesciences® Receives Notice of Allowance for Additional U.S. Patent Related to Its Proprietary Diabetes Neuromodulation Technology
Vagal Neuromodulation Offers a Novel Approach to Treating Type 2 Diabetes and Hypoglycemia Patent Enables Equivalent Efficacy with 10 times Lower Energy Consumption Than Current Device Fully Compatible with Standard Implantable Pulse Generators, Enabling Cost-Effective Development IRVINE, Calif., April 21, 2025 (GLOBE NEWSWIRE) -- ReShape Lifesciences® (Nasdaq: RSLS), the premier physician-led weight loss and metabolic health solutions company, today announced that the Company has received a Notice of Allowance from the U.S. Patent and Trademark Office (USPTO) for patent application 18/069,689, entitled, “High-Frequency Low Duty Cycle Patterns for Neural Regulation.
Neutral
Seeking Alpha
2 weeks ago
ReShape Lifesciences Inc. (RSLS) Earnings Highlights and Strategic Business Update Conference (Transcript)
ReShape Lifesciences Inc. (NASDAQ:RSLS ) Earnings Highlights and Strategic Business Update Conference April 10, 2025 4:30 PM ET Company Participants Michael Miller - IR, Rx Communications Paul Hickey - President and CEO Thomas Stankovich - CFO Operator Good afternoon, and thank you for joining the ReShape Lifesciences Earnings Highlights and Strategic Update Conference Call. I would now like to turn the call over to Michael Miller from Rx Communications.
Neutral
GlobeNewsWire
3 weeks ago
ReShape Lifesciences® Partners with Motion Informatics to Bring AI-Driven Neurorehabilitation Technology to the U.S. Market
ReShape Enters Exclusive U.S. Distribution Agreement in the Neuromuscular Rehabilitation Market ReShape Enters Exclusive U.S. Distribution Agreement in the Neuromuscular Rehabilitation Market
Neutral
GlobeNewsWire
3 weeks ago
ReShape Lifesciences® Reports Year Ended December 31, 2024 Financial Results and Provides Corporate Update
Significant Reduction in Overall Operating Expenses of 41.9% in 2024, Excluding M&A Related Expenses, Compared to 2023
Neutral
Business Wire
1 month ago
RESHAPE LIFESCIENCES INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of ReShape Lifesciences Inc. - RSLS
NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed merger of ReShape Lifesciences Inc. (the “Company”) (NasdaqCM: RSLS) and Vyome Therapeutics, Inc. Under the terms of the Proposed Transaction, ReShape shareholders will own approximately 11.1% of the combined company immediately following the closing of the merger, subject to adjustment based on ReShape's a.
Neutral
GlobeNewsWire
1 month ago
ReShape Lifesciences® Receives Notice of Allowance for U.S. Patent Related to Its Proprietary Diabetes Neuromodulation Technology
Vagal Neuromodulation Provides Route to Treat Type 2 Diabetes and Hypoglycemia Vagal Neuromodulation Provides Route to Treat Type 2 Diabetes and Hypoglycemia
Neutral
GlobeNewsWire
2 months ago
ReShape Lifesciences® Signs Distribution Agreement in Canada With Liaison Medical for its Next-Generation Lap-Band® 2.0 FLEX
Liaison Medical is Among the Largest Surgical Device Distributors in Canada Liaison Medical is Among the Largest Surgical Device Distributors in Canada
Neutral
GlobeNewsWire
2 months ago
ReShape Lifesciences® Announces Pricing of Upsized $6.0 Million Public Offering
IRVINE, Calif., Feb. 15, 2025 (GLOBE NEWSWIRE) -- ReShape Lifesciences ® (“ReShape” or the “Company”) (Nasdaq: RSLS), the premier physician-led weight loss and metabolic health solutions company, today announced the pricing of its public offering of 2,575,107 units at a public offering price of $2.33 per unit. Each unit consists of one common share (or pre-funded warrant to purchase one common share in-lieu thereof) and one warrant to purchase one common share.
Neutral
GlobeNewsWire
2 months ago
ReShape Lifesciences® Granted Key International Patent in Israel for Its Proprietary Diabetes Neuromodulation Technology
Vagal Neuromodulation Provides Path to Treat Type 2 Diabetes and Hypoglycemia Vagal Neuromodulation Provides Path to Treat Type 2 Diabetes and Hypoglycemia
Charts implemented using Lightweight Charts™